Clinical Trials

107 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Carcinoma, Renal Cell × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT05461430 2026-04-13

TraveraRTGx

Travera Inc

Completed
72 enrolled
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Anus Neoplasms, Appendiceal Neoplasms, Ascites, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Stomach Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Small Cell, Carcinoma, Pancreatic Ductal, Gastrointestinal Stromal Tumors

NCT04028479 2024-12-18

ROOT

Taproot Health

Completed
167 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Nasopharyngeal Carcinoma, Adenocarcinoma, Adrenal Gland Neoplasms, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoid Tumor, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Chondrosarcoma, Colonic Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liposarcoma, Liver Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mesothelioma, Multiple Myeloma, Neoplasms, Multiple Endocrine Neoplasia, Neoplasms, Unknown Primary, Ovarian Neoplasms, Pancreatic Neoplasms, Parathyroid Neoplasms, Parotid Neoplasms, Penile Neoplasms, Pharyngeal Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Skin Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Ureteral Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Central Nervous System Neoplasms, Cholangiocarcinoma, Carcinoma, Small Cell, Neuroendocrine Tumors, Brain Stem Neoplasms, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Withdrawn
BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Anus Neoplasms, Appendiceal Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lip Neoplasms, Lung Neoplasms, Mesothelioma, Mouth Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Ductal, Small Cell Lung Carcinoma

NCT04106167 2023-09-21

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Fate Therapeutics

Terminated
20 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma